氯吡格雷对早期急性冠状动脉综合征血清sCD40配体的影响

Effect of early treatment with clopidogrel on serum soluble CD40 ligand level in acute coronary syndromes

目的观察用氯吡格雷(clopidogrel)治疗早期急性冠状动脉综合征(acute coronary syndrome,ACS)对病人血清可溶性CD40配体(soluble CD40ligand,sCD40L)的影响,了解该药对ACS斑块稳定性和免疫炎症抑制的作用。方法128例初次确诊为ACS病人分为常规治疗组62例和氯吡格雷治疗组66例,用酶联免疫吸附测定ACS病人治疗前后血清sCD40L水平的变化。结果氯吡格雷治疗组66例ACS病人治疗后血清sCD40L水平从(11.8±3.1)μg/L下降至(5.7±3.0)μg/L,与常规治疗组比较,差异有统计学意义(P<0.01)。结论使用氯吡格雷治疗早期ACS,可明显降低病人sCD40L水平。

objectives To observe the effect of early treatment with clopidogrel on serum CD40 ligand level in acute coronary syndromes （ACS） and to understand the role of clopidogrel in plaque stability and immunological inflammation inhibition in ACS. Methods 128 cases initially diagnosed as ACS were divided into two groups, 62 cases were treated with routine medicine and 66 cases were treated with clopidogrel plus routine medicine. Serum CD40L levels were determined by enzyme-linked immuno-sorbent assay （ELISA）in all patients. Results Serum CD40L level decreased from 11.8±3.1 μg/L down to 5.7±3,0 μg/L in patients treated with clopidogrel as compared with that in the patients treated with routine medicine（P〈0.01 ）. Conclusions Early treatment of ACS patients with clopidogrel can significantly decrease serum inflammatory cytokines.